Data from a new GSK survey released today highlight a potential blind spot in Respiratory Syncytial Virus (RSV) awareness ...
Positive top-line results from VIBRANT Phase 2 trial of verekitug in CRSwNP reported in September showed statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback